NASDAQ:CRTX - Chiesi USA Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cornerstone Therapeutics Inc. is a specialty pharmaceutical company focused on commercializing products for the hospital, respiratory and related specialty markets. The Company's promoted products include CUROSURF, ZYFLO CR, FACTIVE and SPECTRACEF. On December 30, 2011, the Company acquired Cardiokine, Inc., a specialty pharmaceutical company, focused on developing hospital products for cardiovascular indications. In March 2012, it acquired the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets. In June 2012, the Company acquired EKR Therapeutics, Inc. In February 2014, Chiesi Farmaceutici S.p.A acquired Cornerstone Therapeutics Inc.

Receive CRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:CRTX
CUSIP21924P10
Phone+1-919-6786611

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Chiesi USA (NASDAQ:CRTX) Frequently Asked Questions

What is Chiesi USA's stock symbol?

Chiesi USA trades on the NASDAQ under the ticker symbol "CRTX."

Has Chiesi USA been receiving favorable news coverage?

News stories about CRTX stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chiesi USA earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days.

What other stocks do shareholders of Chiesi USA own?

Who are Chiesi USA's key executives?

Chiesi USA's management team includes the folowing people:
  • Kenneth R. McBean, President (Age 48)
  • Craig Alexander Collard, Chief Executive Officer
  • Alastair S. McEwan, Chief Financial Officer, Treasurer, Secretary (Age 62)
  • Andreas Maetzel, Vice President - Clinical and Regulatory (Age 50)
  • Alan T. Roberts, Vice President - Scientific Affairs (Age 47)
  • Joshua B. Franklin, Vice President - Strategy and Business Development (Age 44)
  • Ugo Di Francesco, Director

How do I buy shares of Chiesi USA?

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chiesi USA's official website?

The official website for Chiesi USA is https://www.chiesiusa.com/.

How can I contact Chiesi USA?

Chiesi USA's mailing address is 1255 Crescent Grn Ste 250, CARY, NC 27518-8128, United States. The specialty pharmaceutical company can be reached via phone at +1-919-6786611.


MarketBeat Community Rating for Chiesi USA (NASDAQ CRTX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about Chiesi USA and other stocks. Vote "Outperform" if you believe CRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Featured Article: What does EPS mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel